Key facts
- This page summarizes Cormorant Asset Management, LP's Form 4 filing for Ambrx Biopharma, Inc. (AMAM).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 Oct 2023, 16:15.
Cormorant Asset Management, LP - 23 Oct 2023 Form 4 Insider Report for Ambrx Biopharma, Inc. (AMAM)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- AMAM
- Reported as of
- 23 Oct 2023
- Net transaction value
- +$9,139,542
- SEC form
- 4
- Accepted by SEC
- 25 Oct 2023, 16:15:18 UTC
- Prior SEC filing
- 19 Sep 2023
- Next SEC filing
- 06 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner, By: Bihua Chen, Managing Member
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Cormorant Asset Management, LP filed Form 4 for Ambrx Biopharma, Inc. (AMAM) on 25 Oct 2023.
Change
- Previous filing in this sequence was filed on 19 Sep 2023.
- Current net transaction value: +$9,139,542.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMAM
transaction
Common Stock
Purchase
- Transaction value
- $9,139,542
- Shares
- +1,307,311
- Change %
- +13%
- Price
- $6.99
- Shares after
- 11,231,000
- Date
- 23 Oct 2023
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $6.57 to $7.10 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund (as defined below).
Footnote F2
The number of shares of common stock of the issuer reported herein give effect to the automatic conversion of each ordinary share of Ambrx Biopharma Cayman, Inc. (formerly Ambrx Biopharma Inc., the "Predecessor Issuer") into one-seventh of one share of common stock of the Issuer in connection with the merger of the Predecessor Issuer into a wholly-owned subsidiary of the issuer on October 11, 2023, as reported in the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 12, 2023.
Footnote F3
Information reported herein relates to shares of common stock owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund III, LP ("Fund III"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund III. Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP III, LLC ("GP III") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Footnote F4
Represents (i) 8,725,040 shares of common stock beneficially owned by the Master Fund and (ii) 2,505,960 shares of common stock beneficially owned by Fund III.